{
    "Name": "Lorazepam/Diphenhydramine/Haloperidol/Metoclopramide Topical Gel",
    "Formula": [
        {
            "IngredientName": "Lorazepam USP CIV",
            "Amount": "0.01 g"
        },
        {
            "IngredientName": "Diphenhydramine Hydrochloride USP",
            "Amount": "0.125 g"
        },
        {
            "IngredientName": "Haloperidol USP",
            "Amount": "0.02 g"
        },
        {
            "IngredientName": "Metoclopramide Hydrochloride USP Monohydrate",
            "Amount": "0.236 g"
        },
        {
            "IngredientName": "Propylene Glycol USP",
            "Amount": "0.5 ml"
        },
        {
            "IngredientName": "Base, PCCA Perme8® Anhydrous Gel",
            "Amount": "q.s. 10 ml"
        }
    ],
    "Procedure": [
        {
            "Step": 1,
            "Instruction": "Using a glass mortar and pestle, triturate Lorazepam, Diphenhydramine Hydrochloride, Haloperidol, and Metoclopramide Hydrochloride together. Add Propylene Glycol and mix well."
        },
        {
            "Step": 2,
            "Instruction": "Add PCCA PermE8 Anhydrous Gel Base to Step 1 in portions and mix well. Use an amount that is approximately 60% of the final volume. For example, if the final volume is 10 mL, use 6 mL of PCCA PermE8 Anhydrous Gel Base."
        },
        {
            "Step": 3,
            "Instruction": "Remove the plunger from a Baxter Exacta-Med 10 mL Oral/Topical Syringe, then transfer the Step 2 mixture into the barrel. Replace the plunger into the barrel, and holding syringe upright, slowly push up the plunger, allowing the air to escape. Measure the volume in the syringe and calculate how much PCCA PermE8 Anhydrous Gel Base is needed to bring to the final volume."
        },
        {
            "Step": 4,
            "Instruction": "In a separate Baxter Exacta-Med 10 mL Oral/Topical Syringe, add the required amount of PCCA PermE8 Anhydrous Gel Base."
        },
        {
            "Step": 5,
            "Instruction": "Connect the syringe in Step 4 to the syringe in Step 3 using an Oral/Oral Adapter."
        },
        {
            "Step": 6,
            "Instruction": "Mix Step 5 back and forth from syringe-to-syringe until a uniform mixture is formed."
        },
        {
            "Step": 7,
            "Instruction": "Dispense the Step 6 final preparation in Baxter Exacta-Med Amber 1 mL Oral/Topical Syringes."
        },
        {
            "Step": 8,
            "Instruction": "Physical description of this preparation: off-white to pale beige gel."
        }
    ],
    "Notes": [
        "Protect from light.",
        "Store in an air-tight, light-resistant container.",
        "Store at controlled room temperature of 20°-25°C.",
        "Lorazepam is incompatible with certain types of plastics such as PVC.",
        "Keep Proper Controlled Substance Records.",
        "For compounded preparations, USP standards dictate that the intended strength must be +/-10% of the labeled API strength.",
        "No claims are made as to the safety or efficacy of this preparation.",
        "The maximum Beyond-Use Date (BUD) after compounding is estimated to be 180 days.",
        "PCCA's Blue Box Warning: This formula has been tested in the PCCA Lab using only PCCA chemicals and proprietary bases. Any variations to this formulation may affect physical integrity, solubility, or result in potency or content uniformity issues."
    ],
    "Literature": [
        "Samanta, M.K., Dube, R., & Suresh, B. (2003). Transdermal drug delivery system of haloperidol to overcome self-induced extrapyramidal syndrome. Drug Development and Industrial Pharmacy, 29(4), 405-415. doi: 10.1081/DDC-120018376",
        "Bleicher, J., Bhaskara, A., Huyck, T., Constantino, S., Bardia, A., Loprinzi, C.L., & Silberstein, P.T. (2008). Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. The Journal of Supportive Oncology, 6(1), 27-32.",
        "Moon, R. B. (2006). ABHR gel in the treatment of nausea and vomiting in the hospice patient. International Journal of Pharmaceutical Compounding, 10(2), 95."
    ]
}